Erratum to: Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor (Br J Pharmacol, (2004), 143, (318-330), 10.1038/sj.bjp.0705956);Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor

British Journal of Pharmacology

Volumn 143, Issue 2, 2004, Pages 318-330

  O'Meara, Sarah J ^a   Kinsella, B Therese ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cancer; Farnesyl protein transferase; Isoprenylation; Prostacyclin; R115777; Ras; Receptor

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CALCIUM; CHAPERONE; CYCLIC AMP; GERANYLGERANYLTRANSFERASE; HDJ 2 PROTEIN; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RECEPTOR SUBTYPE; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 RECEPTOR ALPHA; THROMBOXANE A2 RECEPTOR BETA; TIPIFARNIB; TRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CARBOXY TERMINAL SEQUENCE; CELL STRAIN; CHEMICAL REACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DESENSITIZATION; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; FARNESYLATION; GERANYLGERANYLATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; ISOPRENYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 4744365244     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13681     Document Type: Erratum

References (56)

1. ADJEI, A.A. (2001). Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst., 93, 1062-1074.
2. ADJEI, A.A., DAVIS, J.N., ERLICHMAN, C., SVINGEN, P.A. & KAUFMANN, S.H. (2000). Comparison of potential markers of farnesyltransferase inhibition. Clin. Cancer Res., 6, 2318-2325.
3. ASHAR, H.R., JAMES, L., GRAY, K., CARR, D., BLACK, S., ARMSTRONG, L., BISHOP, W.R. & KIRSCHMEIER, P. (2000). Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J. Biol. Chem., 275, 30451-30457.
4. BOS, J.L. (1989). ras oncogenes in human cancer: a review. Cancer Res., 49, 4682-4689.
5. CHENG, Y., AUSTIN, S.C., ROCCA, B., KOLLER, B.H., COFFMAN, T.M., GROSSER, T., LAWSON, J.A. & FITZGERALD, G.A. (2002). Role of prostacyclin in the cardiovascular response to thromboxane A2. Science, 296, 539-541.
6. CLARKE, S. (1992). Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu. Rev. Biochem., 61, 355-386.
7. COLEMAN, R.A., SMITH, W.L. & NARUMIYA, S. (1994). International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev., 46, 205-229.
8. COX, A.D. & DER, C.J. (1992). The ras/cholesterol connection: implications for ras oncogenicity. Crit. Rev. Oncogen., 3, 365-400.
9. COX, A.D. & DER, C.J. (1997). Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta, 1333, F51-F71.
10. COX, A.D., GARCIA, A.M., WESTWICK, J.K., KOWALCZYK, J.J., LEWIS, M.D., BRENNER, D.A. & DER, C.J. (1994). The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. J. Biol. Chem., 269, 19203-19206.
11. CRUL, M., DE KLERK, G.J., SWART, M., WEINER, L., PALMER, P.A., BOL, C.J., BEIJNEN, J.H. & SCHELLENS, J.H. (2002). Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors. Eur. J. Drug Metab. Pharmacokinet., 27, 61-65.
12. END, D.W. (1999). Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest. New Drugs, 17, 241-258.
13. END, D.W., SMETS, G., TODD, A.V., APPLEGATE, T.L., FUERY, C.J., ANGIBAUD, P., VENET, M., SANZ, G., POIGNET, H., SKRZAT, S., DEVINE, A., WOUTERS, W. & BOWDEN, C. (2001). Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res., 61, 131-137.
14. GAGNON, A.W., KALLAL, L. & BENOVIC, J.L. (1998). Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the beta2-adrenergic receptor. J. Biol. Chem., 273, 6976-6981.
15. GIBBS, J.B. & OLIFF, A. (1997). The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu. Rev. Pharmacol. Toxicol., 37, 143-166.
16. GRAHAM, F.L. & VAN DER EB, A.J. (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology, 52, 456-467.
17. HAYES, J.S., LAWLER, O.A., WALSH, M.T. & KINSELLA, B.T. (1999). The prostacyclin receptor is isoprenylated. Isoprenylation is required for efficient receptor-effector coupling. J. Biol. Chem., 274, 23707-23718.
18. INGLESE, J., GLICKMAN, J.F., LORENZ, W., CARON, M.G. & LEFKOWITZ, R.J. (1992). Isoprenylation of a protein kinase. Requirement of farnesylation/alpha-carboxyl methylation for full enzymatic activity of rhodopsin kinase. J. Biol. Chem., 267, 1422-1425.
19. JAMES, G.L., GOLDSTEIN, J.L. & BROWN, M.S. (1995). Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem., 270, 6221-6226.
20. JAMES, G.L., GOLDSTEIN, J.L., PATHAK, R.K., ANDERSON, R.G. & BROWN, M.S. (1994). P x F, a prenylated protein of peroxisomes. J. Biol. Chem., 269, 14182-14190.
21. JOHNSTON, S.R., HICKISH, T., ELLIS, P., HOUSTON, S., KELLAND, L., DOWSETT, M., SALTER, J., MICHIELS, B., PEREZ-RUIXO, J.J., PALMER, P. & HOWES, A. (2003). Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J. Clin. Oncol., 21, 2492-2499.
22. KANAZAWA, M., TERADA, K., KATO, S. & MORI, M. (1997). HSDJ, a human homolog of DnaJ, is farnesylated and is involved in protein import into mitochondria. J. Biochem. (Tokyo), 121, 890-895.
23. KARP, J.E., KAUFMANN, S.H., ADJEI, A.A., LANCET, J.E., WRIGHT, J.J. & END, D.W. (2001a). Current status of clinical trials of farnesyltransferase inhibitors. Curr. Opin. Oncol., 13, 470-476.
24. KARP, J.E., LANCET, J.E., KAUFMANN, S.H., END, D.W., WRIGHT, J.J., BOL, K., HORAK, I., TIDWELL, M.L., LIESVELD, J., KOTTKE, T.J., ANGE, D., BUDDHARAJU, L., GOJO, I., HIGHSMITH, W.E., BELLY, R.T., HOHL, R.J., RYBAK, M.E., THIBAULT, A. & ROSENBLATT, J. (2001b). Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood, 97, 3361-3369.
25. KELLAND, L.R., SMITH, V., VALENTI, M., PATTERSON, L., CLARKE, P.A., DETRE, S., END, D., HOWES, A.J., DOWSETT, M., WORKMAN, P. & JOHNSTON, S.R. (2001). Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin. Cancer Res., 7, 3544-3550.
26. KINSELLA, B.T., ERDMAN, R.A. & MALTESE, W.A. (1991a). Carboxyl-terminal isoprenylation of ras-related GTP-binding proteins encoded by rac1, rac2, and ralA. J. Biol. Chem., 266, 9786-9794.
27. KINSELLA, B.T., ERDMAN, R.A. & MALTESE, W.A. (1991b). Posttranslational modification of Ha-ras p21 by farnesyl versus geranylgeranyl isoprenoids is determined by the COOH-terminal amino acid. Proc. Natl. Acad. Sci. U.S.A., 88, 8934-8938.
28. KINSELLA, B.T., O'MAHONY, D.J. & FITZGERALD, G.A. (1997). The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J. Pharmacol. Exp. Ther., 281, 957-964.
29. KOHL, N.E. (1999). Farnesyltransferase inhibitors. Preclinical development. Ann. N.Y. Acad. Sci., 886, 91-102.
30. KOHL, N.E., OMER, C.A., CONNER, M.W., ANTHONY, N.J., DAVIDE, J.P., DESOLMS, S.J., GIULIANI, E.A., GOMEZ, R.P., GRAHAM, S.L., HAMILTON, K., HANDT, L.K., HARTMAN, G.D., KOBLAN, K.S., KRAL, A.M., MILLER, P.J., MOSSER, S.D., O'NEILL, T.J., RANDS, E., SCHABER, M.D., GIBBS, J.B. & OLIFF, A. (1995). Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med., 1, 792-797.
31. KOHL, N.E., WILSON, F.R., MOSSER, S.D., GIULIANI, E., DESOLMS, S.J., CONNER, M.W., ANTHONY, N.J., HOLTZ, W.J., GOMEZ, R.P., LEE, T.J., SMITH, R.L., GRAHAM, S.L., HARTMAN, G.D., GIBBS, J.B. & OLIFF, A. (1994). Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. U.S.A., 91, 9141-9145.
32. LAWLER, O.A., MIGGIN, S.M. & KINSELLA, B.T. (2001). The effects of the statins lovastatin and cerivastatin on signalling by the prostanoid IP-receptor. Br. J. Pharmacol., 132, 1639-1649.
33. MALTESE, W.A. & SHERIDAN, K.M. (1990). Isoprenoid modification of G25K (Gp), a low molecular mass GTP-binding protein distinct from p21ras. J. Biol. Chem., 265, 17883-17890.
34. MIGGIN, S.M., LAWLER, O.A. & KINSELLA, B.T. (2002). Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. Eur. J. Biochem., 269, 1714-1725.
35. MOORES, S.L., SCHABER, M.D., MOSSER, S.D., RANDS, E., O'HARA, M.B., GARSKY, V.M., MARSHALL, M.S., POMPLIANO, D.L. & GIBBS, J.B. (1991). Sequence dependence of protein isoprenylation. J. Biol. Chem., 266, 14603-14610.
36. MURATA, T., USHIKUBI, F., MATSUOKA, T., HIRATA, M., YAMASAKI, A., SUGIMOTO, Y., ICHIKAWA, A., AZE, Y., TANAKA, T., YOSHIDA, N., UENO, A., OH-ISHI, S. & NARUMIYA, S. (1997). Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature, 388, 678-682.
37. NAMBA, T., OIDA, H., SUGIMOTO, Y., KAKIZUKA, A., NEGISHI, M., ICHIKAWA, A. & NARUMIYA, S. (1994). cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J. Biol. Chem., 269, 9986-9992.
38. NARUMIYA, S., SUGIMOTO, Y. & USHIKUBI, F. (1999). Prostanoid receptors: structures, properties, and functions. Physiol. Rev., 79, 1193-1226.
39. NORMAN, P. (2002). Tipifarnib (Janssen Pharmaceutica). Curr. Opin. Investig. Drugs, 3, 313-319.
40. OLIFF, A. (1999). Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim. Biophys. Acta, 1423, C19-C30.
41. REESE, J.H. & MALTESE, W.A. (1991). Post-translational modification of proteins by 15-carbon and 20-carbon isoprenoids in three mammalian cell lines. Mol. Cell. Biochem., 104, 109-116.
42. REISS, Y., STRADLEY, S.J., GIERASCH, L.M., BROWN, M.S. & GOLDSTEIN, J.L. (1991). Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. Proc. Natl. Acad. Sci. U.S.A., 88, 732-736.
43. ROWINSKY, E.K., WINDLE, J.J. & VON HOFF, D.D. (1999). Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol., 17, 3631-3652.
44. SAKAI, A., YAJIMA, M. & NISHIO, S. (1990). Cytoprotective effect of TRK-100, a prostacyclin analogue, against chemical injuries in cultured human vascular endothelial cells. Life Sci., 47, 711-719.
45. SEABRA, M.C., GOLDSTEIN, J.L., SUDHOF, T.C. & BROWN, M.S. (1992). Rab geranylgeranyl transferase. A multisubunit enzyme that prenylates GTP-binding proteins terminating in Cys-X-Cys or Cys-Cys. J. Biol. Chem., 267, 14497-14503.
46. TERADA, K. & MORI, M. (2000). Human DnaJ homologs dj2 and dj3, and bag-1 are positive cochaperones of hsc70. J. Biol. Chem., 275, 24728-24734.
47. VANE, J.R. & BOTTING, R.M. (1995). Pharmacodynamic profile of prostacyclin. Am. J. Cardiol., 75, A3-A10.
48. WALSH, M.T. & KINSELLA, B.T. (2000). Regulation of the human prostanoid TPalpha and TPbeta receptor isoforms mediated through activation of the EP(1) and IP receptors. Br. J. Pharmacol., 131, 601-609.
49. WALSH, M.T., FOLEY, J.F. & KINSELLA, B.T. (2000). The alpha, but not the beta, isoform of the human thromboxane A2 receptor is a target for prostacyclin-mediated desensitization, J. Biol. Chem., 275, 20412-20423.
50. WHYTE, D.B., KIRSCHMEIER, P., HOCKENBERRY, T.N., NUNEZ-OLIVA, I., JAMES, L., CATINO, J.J., BISHOP, W.R. & PAI, J.K. (1997). K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem., 272, 14459-14464.
51. WISE, H. & JONES, R.L. (1996). Focus on prostacyclin and its novel mimetics. Trends Pharmacol. Sci., 17, 17-21.
52. XIAO, C.Y., HARA, A., YUHKI, K., FUJINO, T., MA, H., OKADA, Y., TAKAHATA, O., YAMADA, T., MURATA, T., NARUMIYA, S. & USHIKUBI, F. (2001). Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation, 104, 2210-2215.
53. ZACHARY, I. (2001). Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am. J. Physiol. Cell Physiol., 280, C1375-C1386.
54. ZHANG, F.L. & CASEY, P.J. (1996). Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem., 65, 241-269.
55. ZHANG, F.L., KIRSCHMEIER, P., CARR, D., JAMES, L., BOND, R.W., WANG, L., PATTON, R., WINDSOR, W.T., SYTO, R., ZHANG, R. & BISHOP, W.R. (1997). Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J. Biol. Chem., 272, 10232-10239.
56. ZUJEWSKI, J., HORAK, I.D., BOL, C.J., WOESTENBORGHS, R., BOWDEN, C., END, D.W., PIOTROVSKY, V.K., CHIAO, J., BELLY, R.T., TODD, A., KOPP, W.C., KOHLER, D.R., CHOW, C., NOONE, M., HAKIM, F.T., LARKIN, G., GRESS, R.E., NUSSENBLATT, R.B., KREMER, A.B. & COWAN, K.H. (2000). Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol., 18, 927-941.